In addition, CDK12 alterations, found in less than 4% of primary and in no more than 10% of metastatic prostate cancer [61], are associated with higher GS at diagnosis, immunosuppressive tumor microenvironment (TME), and worse prognosis [62], thus suggesting that CDK12 altered PCas have distinctive features from other genomic subtypes of prostate cancer. The gene discussed is CDK12; the disease is neoplasm.